Intermittent parathyroid hormone (1-34) application regulates cAMP-response element binding protein activity to promote the proliferation and osteogenic differentiation of bone mesenchymal stromal cells, via the cAMP/PKA signaling pathway

Chen,Bailing; Lin,Tao; Yang,Xiaoxi; Li,Yiqiang; Xie,Denghui; Cui,Haowen

doi:10.3892/etm.2016.3177

Intermittent parathyroid hormone (1-34) application regulates cAMP-response element binding protein activity to promote the proliferation and osteogenic differentiation of bone mesenchymal stromal cells, via the cAMP/PKA signaling pathway

Authors:
- Bailing Chen
- Tao Lin
- Xiaoxi Yang
- Yiqiang Li
- Denghui Xie
- Haowen Cui
View Affiliations

Affiliations: Department of Spine Surgery, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Spine Surgery, Chinese PLA General Hospital (301 Hospital), Beijing 100853, P.R. China, Department of Orthopedics, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510623, P.R. China, Department of Spine Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, P.R. China
Published online on: March 22, 2016 https://doi.org/10.3892/etm.2016.3177
Pages: 2399-2406

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The potential effects of intermittent parathyroid hormone (1-34) [PTH (1-34)] administration on bone formation have previously been investigated. A number of studies have suggested that the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway is associated with PTH‑induced osteogenic differentiation. However, the precise signaling pathways and molecular mechanism by which PTH (1‑34) induces the osteogenic differentiation of bone mesenchymal stromal cells (BMSCs) remain elusive. The purpose of the present study was to investigate the mechanism underlying the effect of intermittent PTH (1‑34) application on the proliferation and osteogenic differentiation of BMSCs. BMSCs were randomly divided into four groups, as follows: Osteogenic medium (control group); osteogenic medium and intermittent PTH (1-34); osteogenic medium and intermittent PTH (1‑34) plus the adenylyl cyclase activator forskolin; and osteogenic medium and intermittent PTH (1‑34) plus the PKA inhibitor H‑89. A cell proliferation assay revealed that PTH (1‑34) stimulates BMSC proliferation via the cAMP/PKA pathway. Furthermore, reverse transcription‑quantitative polymerase chain reaction, alkaline phosphatase activity testing and cell examination using Alizarin Red S staining demonstrated that PTH (1‑34) administration promotes osteogenic differentiation and mineralization, mediated by the cAMP/PKA pathway. Crucially, the results of western blot analyses suggested that PTH (1‑34) treatment and, to a greater degree, PTH (1-34) plus forskolin treatment caused an increase in phosphorylated cAMP response element binding protein (p‑CREB) expression, but the effect of PTH on p‑CREB expression was blocked by H‑89. In conclusion, the current study demonstrated that intermittent PTH (1‑34) administration regulates downstream proteins, particularly p‑CREB, in the cAMP/PKA signaling pathway, to enhance the proliferation, osteogenic differentiation and mineralization of BMSCs.

View Figures

View References

1	Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA and McCauley LK: Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone. 42:806–818. 2008. View Article : Google Scholar : PubMed/NCBI
2	Compston JE: Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure. Bone. 40:1447–1452. 2007. View Article : Google Scholar : PubMed/NCBI
3	Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, et al: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344:1434–1441. 2001. View Article : Google Scholar : PubMed/NCBI
4	Jiang Y, Zhao J, Liao EY, Dai RC, Wu XP and Genant HK: Application of micro-CT assessment of 3-D bone microstructure in preclinical and clinical studies. J Bone Miner Metab. 23(Suppl): S122–S131. 2005. View Article : Google Scholar
5	Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM and Manolagas SC: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 104:439–446. 1999. View Article : Google Scholar : PubMed/NCBI
6	Kaback LA, do Soung Y, Naik A, Geneau G, Schwarz EM, Rosier RN, O'Keefe RJ and Drissi H: Teriparatide (1–34 human PTH) regulation of osterix during fracture repair. J Cell Biochem. 105:219–226. 2008. View Article : Google Scholar : PubMed/NCBI
7	Yang C, Frei H, Burt HM and Rossi F: Effects of continuous and pulsatile PTH treatments on rat bone marrow stromal cells. Biochem Biophys Res Commun. 380:791–796. 2009. View Article : Google Scholar : PubMed/NCBI
8	Wang BL, Dai CL, Quan JX, Zhu ZF, Zheng F, Zhang HX, Guo SY, Guo G, Zhang JY and Qiu MC: Parathyroid hormone regulates osterix and Runx2 mRNA expression predominantly through protein kinase A signaling in osteoblast-like cells. J Endocrinol Invest. 29:101–108. 2006. View Article : Google Scholar : PubMed/NCBI
9	Nakao Y, Koike T, Ohta Y, Manaka T, Imai Y and Takaoka K: Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3′,5′-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells. Bone. 44:872–877. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT and Onyia JE: Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 95:1178–1190. 2005. View Article : Google Scholar : PubMed/NCBI
11	Inoue Y, Canaff L, Hendy GN, Hisa I, Sugimoto T, Chihara K and Kaji H: Role of Smad3, acting independently of transforming growth factor-beta, in the early induction of Wnt-beta-catenin signaling by parathyroid hormone in mouse osteoblastic cells. J Cell Biochem. 108:285–294. 2009. View Article : Google Scholar : PubMed/NCBI
12	Tian Y, Xu Y, Fu Q and He M: Parathyroid hormone regulates osteoblast differentiation in a Wnt/β-catenin-dependent manner. Mol Cell Biochem. 355:211–216. 2011. View Article : Google Scholar : PubMed/NCBI
13	Miao D, Tong XK, Chan GK, Panda D, McPherson PS and Goltzman D: Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem. 276:32204–32213. 2001. View Article : Google Scholar : PubMed/NCBI
14	Rey A, Manen D, Rizzoli R, Ferrari SL and Caverzasio J: Evidences for a role of p38 MAP kinase in the stimulation of alkaline phosphatase and matrix mineralization induced by parathyroid hormone in osteoblastic cells. Bone. 41:59–67. 2007. View Article : Google Scholar : PubMed/NCBI
15	Siddappa R, Martens A, Doorn J, Leusink A, Olivo C, Licht R, van Rijn L, Gaspar C, Fodde R, Janssen F, et al: cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proc Natl Acad Sci USA. 105:7281–7286. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kao R, Lu W, Louie A and Nissenson R: Cyclic AMP signaling in bone marrow stromal cells has reciprocal effects on the ability of mesenchymal stem cells to differentiate into mature osteoblasts versus mature adipocytes. Endocrine. 42:622–636. 2012. View Article : Google Scholar : PubMed/NCBI
17	Doorn J, Siddappa R, van Blitterswijk CA and de Boer J: Forskolin enhances in vivo bone formation by human mesenchymal stromal cells. Tissue Eng Part A. 18:558–567. 2012. View Article : Google Scholar : PubMed/NCBI
18	Yang DC, Tsay HJ, Lin SY, Chiou SH, Li MJ, Chang TJ and Hung SC: cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS One. 3:e15402008. View Article : Google Scholar : PubMed/NCBI
19	Potts JT: Parathyroid hormone: Past and present. J Endocrinol. 187:311–325. 2005. View Article : Google Scholar : PubMed/NCBI
20	Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:109–110. 1983. View Article : Google Scholar : PubMed/NCBI
21	Kawane T, Mimura J, Yanagawa T, Fujii-Kuriyama Y and Horiuchi N: Parathyroid hormone (PTH) down-regulates PTH/PTH-related protein receptor gene expression in UMR-106 osteoblast-like cells via a 3′,5′-cyclic adenosine monophosphate-dependent, protein kinase A-independent pathway. J Endocrinol. 178:247–256. 2003. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H and Shimada Y: Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone. 42:90–97. 2008. View Article : Google Scholar : PubMed/NCBI
24	Rickard DJ, Wang FL, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta B, Stroup GB, Kumar S and Nuttall ME: Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone. 39:1361–1372. 2006. View Article : Google Scholar : PubMed/NCBI
25	Baron R and Hesse E: Update on bone anabolics in osteoporosis treatment: Rationale, current status, and perspectives. J Clin Endocrinol Metab. 97:311–325. 2012. View Article : Google Scholar : PubMed/NCBI
26	Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, Suda T, Yoshiki S and Takahashi HE: Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 15:717–723. 1994. View Article : Google Scholar : PubMed/NCBI
27	Nakashima K and de Crombrugghe B: Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet. 19:458–466. 2003. View Article : Google Scholar : PubMed/NCBI
28	Marie PJ: Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys. 473:98–105. 2008. View Article : Google Scholar : PubMed/NCBI
29	Krishnan V, Moore TL, Ma YL, Helvering LM, Frolik CA, Valasek KM, Ducy P and Geiser AG: Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol. 17:423–435. 2003. View Article : Google Scholar : PubMed/NCBI
30	Stucki U, Schmid J, Hämmerle CF and Lang NP: Temporal and local appearance of alkaline phosphatase activity in early stages of guided bone regeneration. A descriptive histochemical study in humans. Clin Oral Implants Res. 12:121–127. 2001. View Article : Google Scholar : PubMed/NCBI
31	Franceschi RT: The developmental control of osteoblast-specific gene expression: Role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral Biol Med. 10:40–57. 1999. View Article : Google Scholar : PubMed/NCBI
32	Zhou Y, Guan X, Zhu Z, Gao S, Zhang C, Li C, Zhou K, Hou W and Yu H: Osteogenic differentiation of bone marrow-derived mesenchymal stromal cells on bone-derived scaffolds: Effect of microvibration and role of ERK1/2 activation. Eur Cell Mater. 22:12–25. 2011.PubMed/NCBI
33	Zhang C, Li J, Zhang L, Zhou Y, Hou W, Quan H, Li X, Chen Y and Yu H: Effects of mechanical vibration on proliferation and osteogenic differentiation of human periodontal ligament stem cells. Arch Oral Biol. 57:1395–1407. 2012. View Article : Google Scholar : PubMed/NCBI
34	Owen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, Kennedy MB, Pockwinse S, Lian JB and Stein GS: Progressive development of the rat osteoblast phenotype in vitro: Reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol. 143:420–430. 1990. View Article : Google Scholar : PubMed/NCBI
35	Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G and Silva AJ: Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell. 79:59–68. 1994. View Article : Google Scholar : PubMed/NCBI
36	Tyson DR, Swarthout JT and Partridge NC: Increased osteoblastic c-fos expression by parathyroid hormone requires protein kinase A phosphorylation of the cyclic adenosine 3′,5′-monophosphate response element-binding protein at serine 133. Endocrinology. 140:1255–1261. 1999. View Article : Google Scholar : PubMed/NCBI